Objective: Arteriovenous grafts remain reliable substitutes for permanent hemodialysis access in patients without a suitable autogenous conduit. Advances in conduit design and endovascular management of access-related complications question the preference for synthetic conduits over biologic grafts in contemporary practice. In this study, we compared outcomes between a bovine carotid artery (BCA) biologic graft and expanded polytetrafluoroethylene (ePTFE) grafts for hemodialysis access in a recent cohort of patients.
The hemodialysis-dependent population is an ever expanding one. More than 600,000 patients in the United States have end-stage renal disease, and an estimated 100,000 new cases are reported annually. 1 Despite the well-recognized benefits of renal transplantation, only a limited proportion of patients with end-stage renal disease are able to receive compatible and durable transplants; hence >60% of these patients require maintenance on hemodialysis. 1 The evaluation of hemodialysis access conduits remains a critical and evolving subject. Repetitive puncture and the unique physiologic milieu of dialysis patients place a high premium on the most durable conduits for access. The type of vascular access used for hemodialysis has also been identified as key determinant of survival in these patients. [2] [3] [4] [5] Professional bodies, including the Society for Vascular Surgery and the National Kidney Foundation, as well as the Centers for Medicare and Medicaid Services have recommended the use of permanent access, with an arteriovenous fistula (AVF) or arteriovenous graft (AVG) as the preferred mode of dialysis access instead of a catheter. [6] [7] [8] This preference is informed by the lower risks Although AVF is the most preferred mode of access, not all patients are good candidates for an AVF because of inadequate veins. In such patients, AVGs serve as alternatives. The push for increasing use of permanent access implies that surgeons and their patients are increasingly faced with the choice of competing conduits. Recent advances have been made in the design and techniques for placement and use of xenografts for hemodialysis access. Progress has also been made in endovascular management of access-related complications.
Despite the widespread use of synthetic AVGs, such as expanded polytetrafluoroethylene (ePTFE), in contemporary practice, there is little evidence to support their superiority over decellularized xenografts in this era. The need for current evidence to inform conduit choice is critical. The objective of this study was to evaluate the durability of synthetic AVG (ePTFE) vs bovine carotid artery (BCA) grafts for hemodialysis access in a recent cohort of patients.
METHODS
A retrospective analysis was performed of all patients who received AVGs for dialysis access because they were not candidates for native AVF at Johns Hopkins Bayview Medical Center between January 1, 2011, and June 30, 2014. In accordance with national guidelines, an AVF, including the use of basilic and brachial veins, are the preferred dialysis access conduit in our center. AVGs are used in patients whose anatomy precludes the use of an AVF based on the size of their veins measured during preoperative and intraoperative vein mapping and clinical assessment. AVGs are also used in patients in whom multiple fistulas have failed and bilateral AVF options have been exhausted. This study was approved by the Johns Hopkins Institutional Review Board and the contributing dialysis access centers. The need for individual patient consent was waived.
Electronic medical records at the time of surgery were abstracted for the demographic and medical characteristics listed in Table I . All access placement operations were performed by two senior surgeons according to National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines for AVG creation. 7 The BCA graft used was the Artegraft (Artegraft, Inc, North Brunswick, NJ), and the PTFE grafts used were the Flixene (Maquet-Atrium Medical, Hudson, NH), Advanta VXT (Maquet-Atrium), GORE-TEXStretch Vascular Graft For Vascular Access (W. L. Gore and Associates, Flagstaff, Ariz), or Venaflo (Bard Peripheral Vascular, Tempe, Ariz). The choice of graft used was at the surgeons' discretion.
Graft placement and follow-up. The configurations of grafts placed were C-shaped, with an arterial anastomosis to the brachial artery slightly proximal or at the antecubital fossa and venous anastomosis to the axillary vein in the upper arm, looped brachial artery to cephalic vein in the forearm, and looped femoral artery to femoral vein in the thigh.
Patients were examined at the end of AVG placement surgery and at postoperative weeks 2, 4, and 6. Examination for thrills, bruits, circulatory, and neurologic function was performed at each visit. Hemodialysis via the graft was permitted in the absence of complications after the manufacturer's recommended waiting time had elapsed to allow adequate tissue-to-graft incorporation and perigraft swelling had subsided to allow for graft palpation. Subsequent graft cannulation was performed in accordance with KDOQI guidelines.
Graft functionality was monitored by nephrologists or trained dialysis nurses. Difficulty during dialysis, such as suboptimal flow or excessive bleeding, absence of a thrill or bruit, triggered subsequent evaluation. When necessary, patients underwent duplex ultrasound imaging for graft evaluation. A fistulogram was performed for significant stenosis established on duplex. The grafts were monitored for the occurrence of stenosis, thrombosis, infection, pseudoaneurysm, or abandonment. Also noted were the interventions required to maintain patency (angioplasty, thrombectomy, thrombolysis, or revision), receipt of a renal transplant, or death. Our outcomes of interest were primary, primary assisted, and secondary patency. These were defined and analyzed in accordance with reporting standards published by the Society for Vascular Surgery. 9 Primary patency was defined as the interval from graft placement to the first intervention performed to relieve stenosis, with or without occlusion. Primary assisted patency was defined as the interval from graft placement to the first episode of occlusion. Secondary patency was defined as the interval from graft placement to graft abandonment. Secondary outcomes were graft infection necessitating intravenous antibiotics or excision, or both, steal requiring intervention (banding, distal revascularization, and interval ligation), and pseudoaneurysm formation. Treatment of graft-related complications was performed according to KDOQI guidelines. 7 Death was verified by matching with the Social Security Death Index. 
RESULTS
Patient characteristics. During the 3.5-year study period, 120 AVGs were placed in 98 patients for hemodialysis access. Of these, 52 (43%) were BCA and 68 (57%) were ePTFE grafts. The cohort was a mean age of 59 years (SD, 13.7; range, 12-88 years). Most patients were male (BCA: 60% vs ePTFE: 54%; P ¼ .57), black (BCA: 79% vs ePTFE: 74%; P ¼ .76), and diabetic (BCA: 64% vs ePTFE: 63%; P ¼ .98). Most grafts (63%) were placed in the upper arm, 11% were placed in the forearm, and 26% in the lower extremities (LEs). The characteristics of patients in both treatment groups were similar, as reported in Table I . Mean patient follow up time was 8 months (SD, 7.2; range, 1-24 months) for BCA and 7 months (SD, 7.2; range 1-24 months) for ePTFE.
Outcomes. Successful graft use for dialysis was 96% (95% confidence interval [CI], 90%-100%) for BCA and 84% (95% CI, 74%-93%) for ePTFE (P ¼ .055). Average time to graft use for dialysis was 4.8 weeks (SD, 4.0; median, 4.3; interquartile range [IQR], 2.0-6.6 weeks) for BCA and 2.9 weeks (SD, 2.4; median, 3.5; IQR, 2.0-4.9 weeks) for ePTFE (P ¼ .002). Comparing BCA vs ePTFE, the unadjusted Kaplan-Meier estimates of primary patency were 36% vs 46% at 6 months, 30% vs 43% at 12 months, and 16% vs 29% at 24 months (P ¼ .27; Fig 1) . Primary assisted patency was 43% vs 48% at 6 months, 36% vs 45% at 12 months, and 24% vs 35% at 24 months for BCA vs ePTFE (P ¼ .57; Fig 2) . Secondary patency was 71% vs 51% at 6 months, 67% vs 48% at 12 months, and 67% vs 38% at 24 months for BCA vs ePTFE (P ¼ .05; Fig 3) . The mean number of interventions performed to achieve these patency rates was 1.2 (95% CI, 0.57-1.89; median, 1; IQR, 0-1) for BCA and 0.85 (95% CI, 0.52-1.18; median: 0; IQR, 0-1) for ePTFE (P ¼ .27). The proportion of grafts that required interventions to maintain patency was 58% for BCA and 47% for ePTFE (P ¼ .25).
The multivariable Cox regression analyses adjusting for patient and graft characteristics (Table II) (Table III) were higher body mass index (aHR, 1.06; 95% CI, 1.00-1.11; P ¼ .04) and hyperlipidemia (aHR, 2.94; 95% CI, 1.27-6.76; P ¼ .01).
The graft infection rate during the study period was 15% for BCA and 21% for ePTFE (P ¼ .47). Graft infection for BCA vs ePTFE did not differ by location: 17% vs 20% in the upper arm (P ¼ .78), 0% vs 29% in the forearm (P ¼ .24), and 29% vs 15% in the LE (P ¼ .41). Multivariable logistic regression confirmed that the infection rate for ePTFE (HR, 1.23; 95% CI, 0.43-3.56; P ¼ .70) was not significantly different from BCA. Steal occurred in two BCA grafts (4%) and in four ePTFE grafts (6%; P ¼ .61). There was no significant difference in this outcome for ePTFE (adjusted odds ratio, 1.81; 95% CI, 0.14-23.38; P ¼ .65) compared with BCA after adjustment for patient and graft characteristics. Pseudoaneurysms occurred in two BCA grafts (4%) and in five ePTFE grafts (7%; P ¼ .42). There was also no significant difference in this outcome comparing ePTFE (adjusted odds ratio, 1.21; 95% CI, 0.11-13.08; P ¼ .87) vs BCA in the adjusted analyses.
Absolute all-cause mortality during the study period was 8% (95% CI, 0.4%-14.9%) for the BCA group and 27% (95% CI, 16.0%-37.0%) for the ePTFE group (P ¼ .01). The unadjusted Kaplan-Meier estimate of patient survival was 87% for BCA and 54% for ePTFE at 2 years (Fig 4) . The adjusted Cox regression analyses showed higher mortality for ePTFE than for BCA (HR, 4.7; 95% CI, 1. 
DISCUSSION
The use of BCA biological grafts began in the 1970; however, their use declined with the development of grafts made from synthetic polymers such as ePTFE. [10] [11] [12] [13] [14] [15] Although ePTFE conduits remain the dominant AVG in use today, resurgence in the use of biologic grafts has been observed. This retrospective study presents an extensive investigation of differences in outcomes between BCA and ePTFE vascular access conduits as well as insight into factors limiting graft patency. In this study of a recent cohort of patients, we have shown similar primary and primary assisted patency between ePTFE and BCA grafts. However, secondary patency was significantly higher for BCA compared with ePTFE.
Very little has been done to evaluate the durability of BCA grafts in recent times. Most of the studies that have evaluated patency of BCA were performed in the 1970s and 1980s, and results for primary patency are largely unreported from that era. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In a recent randomized study of 26 BCA and 27 ePTFE grafts published in 2011, Kennealey et al 21 reported 1-year primary patency of 61% for BCA and 10% for ePTFE grafts in contrast to 30% for BCA and 43% for ePTFE in the current study. Other randomized and observational studies of ePTFE report primary patency ranging from 37% to 56%, and our findings fall within this range.
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The primary assisted patency at 1 year for BCA of 36% in our study is lower than the 61% reported from the recent randomized study. 21 In contrast, primary assisted patency for ePTFE in this study (45%) was double that reported from the randomized study (21%). 21 Differences in surgical technique and institutional preferences likely contribute to the variability in reported findings. Other randomized studies that evaluated outcomes of ePTFEd although not in comparison with BCAdfailed to report primary assisted patency. 22, 24 We are thus unable to compare our outcomes with those studies for this end point. This reiterates the need to abide by uniform reporting guidelines such as those provided by the Society for Vascular Surgery. The higher secondary patency for BCA relative to ePTFE depicts a higher likelihood of graft abandonment for ePTFE. To our knowledge, this is the first report of an advantage of BCA over ePTFE with regards to secondary patency. Results from the recent randomized study showed a benefit with BCA for primary and primary assisted patency but statistically equivalent results for secondary patency. 21 In that study, secondary patency at 1 year was 60% for BCA and 73% for ePTFE in contrast to 67% for BCA vs 48% for ePTFE in the current study (P ¼ .05). Studies that evaluated the first generation of BCA grafts reported overall graft survival of 70% to 100% and significant variation in durations of followup. 11, 13, 14, [17] [18] [19] 26 Head-to-head comparisons of BCA vs ePTFE in the remote era revealed multiple conflicting results. Some studies from that period showed superior or equivalent outcomes for BCA, whereas others refuted those findings, thus setting the stage for equipoise in practice. 15, [27] [28] [29] The reasons proposed to account for the eventual decline in use of BCA include frequent thromboses, aneurysmal degeneration, decreased salvageability, higher cost, and nonavailability in different dimensions. 27 ,28,30,31 Surgeon experience with biologic conduit use was also identified as a contributor at that time. It was opined that BCA was abandoned in general before operators ascended to points on the learning curve at which favorable outcomes might have been obtained. 15 The findings of the current study show that the durability of BCA is superior with experienced operators in this era. Differences in cost likely persist, and this deserves objective and rigorous comparison. 32 Nonetheless, placement of a more durable graft attracts lower cost in the long-term. The emphasis on durability and lower long-term cost is supported by the comprehensive end-stage renal disease care and accountable care organization models recently launched by Centers for Medicare and Medicaid services in accordance with the Affordable Care Act. 33 Improvements in the diagnosis of failing conduits and endovascular interventions have improved our ability to rescue failing grafts from subsequent occlusion and abandonment. The benefit of salvage interventions was more pronounced for BCA, as shown in the improvement of patency from 28% (primary) to 38% (primary assisted) and 67% (secondary) at 1 year. Our results show that ePTFE grafts were less amenable to these interventions despite an average of one intervention per graft to improve patency. The durability of BCA cannot be separated from the biologic mimicry that this conduit alternative confers. The poorer outcome in the ePTFE group might be related to the higher incidence of neointimal hyperplasia in synthetic conduits, as has been described previously. 21, 34 The mismatch of elastic properties between synthetic and native vessels at the points of anastomoses causes a disruption in vessel resistance to axial and shear stress. This causes cell proliferation and a negative effect on laminal flow, thus serving as a primer for graft failure. 35, 36 The future of durable AVGs is highly dependent on the development of conduits that achieve better biologic and physical mimicry of native vessels to overcome these impediments. As we have shown, patients with a high body mass index and those with hyperlipidemia pose a potential target for improvement in outcomes. These patients deserve extra vigilance and prompt intervention. A significant portion of the patients in the current study were hyperlipidemic, and this comorbidity was associated with a nearly threefold increase in graft failure. This finding echoes the need for surgeons to remind their patients and collaborating health care providers about the benefit of tight lipid control on survival of the AVG. This is in addition to the known benefits of optimal management of comorbidities on overall patient survival.
Our finding of a fivefold increase in mortality associated with ePTFE is an interesting one. In this study, PTFE was not offered to sicker patients, and the higher mortality in this group persisted despite adjustment for patient characteristics. Nonetheless, the difference in survival should be interpreted with caution in view of the multifactorial causes of death in dialysis patients. We recommend further examination of this finding under strict conditions that take into account factors that have been shown to affect patient survival such as adequacy of dialysis, nutrition, predialysis care, and bridging use of dialysis catheters. 3 Time to graft use in this study was $2 weeks for PTFE and $4 weeks for BCA. Although AVGs are generally considered ready for cannulation within 10 to 14 days, waiting times >14 days are not uncommon and are largely driven by patient-specific differences in time to resolution of perigraft swelling and allowance for adequate tissue incorporation according to the provider's experience. 37 The prevalence of LE grafts was not statistically different in the BCA and ePTFE groups (33% vs 22%; P ¼ .58), and our results were adjusted for graft location. The inclusion of a marginally higher proportion of LE grafts in the BCA group likely underestimates the advantage of BCA compared with PTFE in view of the lower durability of LE grafts compared with upper extremity grafts, as reported previously. 38 LE grafts were included in this study to compensate for the sample size constraints. The assessment of BCA vs PTFE within strata of upper and lower extremity leaves room for further study in larger cohorts of patients. We acknowledge that this study is limited by the retrospective design and relatively small sample size. This cannot be ruled out as a potential cause of our inability to detect significant differences in primary and primary assisted patency. The choice of conduit was at the surgeons' discretion; however, BCA and PTFE graft use was similar among the surgeons. There were no outcome differences between surgeons or anastomotic techniques. These data did not reveal a learning curve with regards to outcomes. We do not have data on the cellular causes of stenosis, thrombosis, and graft failure.
This study does not take medication use into consideration. We believe that medication use beyond the time of access creation plays the more significant role compared with medication use at the time of surgery. We were unable to reliably ascertain patients' use of relevant medications beyond surgery, hence this limitation. Mean follow-up was approximately 1 year; thus, caution is needed when interpreting our findings beyond this time point.
This analysis did not take into consideration the type and number of prior vascular accesses and the effect this might have on subsequent graft abandonment. These findings might not be applicable to other types of PTFE grafts not included in this study. These limitations leave room for further investigation in a larger cohort of AVGs with longer follow-up, as we are currently doing in a prospective randomized study at our institution. Despite these limitations, our study has shown that BCA is a durable alternative to AVF in contemporary practice. 
